Stroke prevention, blood cholesterol, and statins

被引:110
作者
Amarenco, P
Lavallée, P
Touboul, PJ
机构
[1] Hop Xavier Bichat, Dept Neurol, F-75018 Paris, France
[2] Hop Xavier Bichat, Stroke Ctr, F-75018 Paris, France
[3] Univ Paris 07, Sch Med, F-75018 Paris, France
[4] Format Rech Neurol Vasc, Paris, France
关键词
D O I
10.1016/S1474-4422(04)00734-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The risk of stroke increases with age, and hence the disease particularly affects the elderly, who are also at high risk for coronary heart disease. Epidemiological and observational studies have not shown a clear association between cholesterol concentrations and all causes of stroke. Large, long-term statin trials in patients with established or high risk for coronary heart disease have shown that statins decrease stroke incidence. These statin trials in a combined total of 70 020 patients indicate relative and absolute risk reductions for stroke of 21% and 0.9%, respectively. By comparison, the number of strokes prevented per 1000 patients treated for 5 years in patients with coronary heart disease is nine for statins versus 17.3 for antiplatelet drugs and 17 for anti hypertensive drugs. Although the Heart Protection Study showed that statins lower the risk of major coronary events in patients with a previous stroke, statins may not lower stroke recurrence in these patients. In this review, we discuss the potential reasons for the effects of statins on stroke and the mechanisms of action. Treatment strategies on the basis of global cardiovascular risk may be most effective. Additional studies in patients representative of the typical stroke population are needed.
引用
收藏
页码:271 / 278
页数:8
相关论文
共 54 条
  • [1] EFFECT OF CHOLESTEROL-LOWERING MEDICATIONS ON PROGRESSION OF MILD ATHEROSCLEROTIC LESIONS OF THE CAROTID ARTERIES AND ON THE RISK OF STROKE
    ADAMS, HP
    BYINGTON, RP
    HOEN, H
    DEMPSEY, R
    FURBERG, CD
    [J]. CEREBROVASCULAR DISEASES, 1995, 5 (03) : 171 - 177
  • [2] Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice
    Amin-Hanjani, S
    Stagliano, NE
    Yamada, M
    Huang, PL
    Liao, JK
    Moskowitz, MA
    [J]. STROKE, 2001, 32 (04) : 980 - 985
  • [3] [Anonymous], 2000, J Atheroscler Thromb, V7, P110
  • [4] [Anonymous], 2002, JAMA
  • [5] Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention - The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study
    Athyros, VG
    Papageorgiou, AA
    Mercouris, BR
    Athyrou, VV
    Symeonidis, AN
    Basayannis, EO
    Demitriadis, DS
    Kontopoulos, AG
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (04) : 220 - 228
  • [6] CHOLESTEROL REDUCTION AND THE RISK FOR STROKE IN MEN - A METAANALYSIS OF RANDOMIZED, CONTROLLED TRIALS
    ATKINS, D
    PSATY, BM
    KOEPSELL, TD
    LONGSTRETH, WT
    LARSON, EB
    [J]. ANNALS OF INTERNAL MEDICINE, 1993, 119 (02) : 136 - 145
  • [7] Byington RP, 2001, CIRCULATION, V103, P387
  • [8] Collins R, 2004, LANCET, V363, P757
  • [9] Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
  • [10] Collins R, 2003, LANCET, V361, P2005